Exelixis
Price & Volume
Stats
See moreOpen | $35.50 |
Previous Close | $34.84 |
Day Range | $33.84-$35.87 |
52W Range | $20.14-$40.02 |
Market Cap | $9.7B |
Shares Short | 13M |
Financials
See moreRevenue (12 Mos) | $2.1B |
Revenue Growth (YoY) | 18.2% |
Gross Profit (12 Mos) | $2B |
Diluted EPS | $1.76 |
News
See moreYahoo Finance • 2 months ago
Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?
Yahoo Finance • 2 months ago
Exelixis Stock Falls as Oppenheimer Downgrades Over Drug Differentiation Concerns
Yahoo Finance • 7 months ago
Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine
Yahoo Finance • 8 months ago
Is Caligan Partners Bullish on Exelixis Inc (EXEL) Right Now?
About
CEO | Dr. Michael M. Morrissey Ph.D. |
CFO | Mr. Christopher J. Senner |
Address | 1851 Harbor Bay Parkway, Alameda, CA, United States, 94502 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 1,147 |
